Key takeaways
- FDA staff recorded that TB-500 is promoted online for many uses; the studies we found that gave TB-500 or its sequence are cell and animal work, plus one uncontrolled report of three patients.
- The 2003 mouse study used the sequence without the acetyl group that FDA and HHS documents give TB-500, and FDA staff say its results “cannot be directly extrapolated” to TB-500.
- In a 2024 cell study summarised by FDA staff, scratch closure with TB-500 did not differ significantly from the control solution; one of its breakdown products produced a small, significant change. A cell result is not evidence of an effect in people.
- In PubMed (21 November 2026), we found three animal studies from 2025 and 2026 that name TB-500, each in a different model measuring different things; none tested it in people.
- We found no published controlled study of TB-500 in people (21 November 2026); a placebo-controlled trial began in February 2026 and has no results.
01TB-500 claims at a glance: how far the research has gone
How far the research on TB-500 has gone, dated 21 November 2026.
Each row counts the studies cited on this page that gave TB-500, or its sequence in any form, and measured an effect; two papers appear in both the cell and the animal row. Bar lengths show order only, not a score, and a row with no qualifying study is drawn at 0%. Only the 2024 cell study says in its abstract that it used the acetylated fragment FDA and HHS documents call TB-500.
Source: FDA’s 2026 review of TB-500, the studies in the table below, and PubMed and ClinicalTrials.gov searches of 21 Nov 2026.
If you searched “tb 500 benefits”, the plain version is this: the studies behind the claims measured specific things in cells and animals, often with a different form of the molecule, and none was a controlled study in people. Each study is below, with what it measured and what it cannot tell you.
02What did the main TB-500 studies measure, and in which models?
Three areas the claims cover, the main study for each, and the model it used. Each card names what was measured, not what to expect.
Skin wounds in old mice
The seven-amino-acid sequence, without the acetyl group FDA and HHS documents give TB-500, and the full protein were tested in 26-month-old mice with small skin wounds. FDA staff summarise the measures: closure of the skin surface and collagen in tissue samples at day 7.
Tendon after surgical repair
Rats had the Achilles tendon cut and repaired, then received TB-500, BPC-157, both or neither, eight per group. At four weeks the study measured the load the tendon held before failing and scored the tissue under the microscope.
Scratch closure in cultured cells
A layer of fibroblasts was scratched and kept with TB-500 or a control solution for eight hours. The measure was how far the scratch closed; the same study tracked TB-500’s breakdown products in rat urine.
Skin, 2003 (T3). FDA staff note that acetylation can change a peptide’s lifespan, folding and binding, so these results “cannot be directly extrapolated” to TB-500, and that the study did not compare different amounts.
Tendon, 2026 (T3). The paper calls its material “synthetic thymosin beta-4 (TB-500)” without saying, in its abstract, whether that was the fragment or the full protein, which FDA staff say “are not the same substance”. The authors call it an “exploratory rat model study”. Human data on this is lacking.
Cells, 2024 (T4). As FDA staff summarise it, scratch closure with TB-500 did not differ significantly from the control solution, while one of its breakdown products, N-acetylated LKKTE, produced a small, significant change. The authors suggest that activity reported for TB-500 in earlier papers may come from that breakdown product. A cell study is not evidence of an effect in people.
What TB-500 is, and why its name is confused with the full protein: the TB-500 guide.
03Study by study: molecule, model, measure, limit
One row per study cited here that gave TB-500 or its sequence. Rows name what was measured, not what to expect.
| Area and what was measured | Study | Molecule tested | Model and n | Tier | Limit |
|---|---|---|---|---|---|
| Skin: closure of the skin surface, collagen | Philp et al., 2003 | The sequence without the acetyl group; the full protein | Mice aged 26 months; n not given in the abstract | T3 | FDA staff: “cannot be directly extrapolated” to TB-500 |
| Liver cells: activation, growth and migration signals | Shah et al., 2018 | The sequence without the acetyl group | Human hepatic stellate cells, in culture | T4 | Cells only; no animal or human measure |
| Cell migration: scratch closure, cell toxicity | Rahaman et al., 2024 | Ac-LKKTETQ, which the authors call TB-500, and its breakdown products | Fibroblasts in culture; rats, for breakdown products in urine | T4 | FDA staff report no significant difference from the control solution for TB-500 itself |
| Eye surface: cell migration and growth, surface barrier | Lu et al., 2025 | A modified molecule: the sequence joined to a gel-forming chemical group | Human eye-surface cells; an animal model of chemical injury to the eye (species and n not in the abstract) | T4, T3 | A different molecule from TB-500; one study |
| Brain: nerve-cell structure, immune-cell signalling, maze and object-recognition tests | Ou et al., 2026 | Described as TB500; form not stated in the abstract | Nerve and immune cells; 5×FAD mice, a genetically modified strain (n not in the abstract) | T4, T3 | One study from one group; nothing in people |
| Tendon: load to failure, tissue scores, collagen types I and III | Biçer et al., 2026 | Described as “synthetic thymosin beta-4 (TB-500)”; form not stated | Rats with a cut and repaired Achilles tendon; 32 animals, 8 per group; 4 weeks | T3 | The authors call it exploratory; human data on this is lacking |
| People: the course of each case, adverse events | Froum et al., 2026 | TB-500 with BPC-157 and three other agents | Three patients, no control group | T2 | The authors: causality “cannot be established” |
| People: adverse events (registered trial) | NCT07487363 | TB-500 | Planned for 80 patients aged 40 to 75, no healthy volunteers; randomised, placebo-controlled | No results | Recruiting since February 2026 |
T2 is small or uncontrolled human research, T3 is animal studies and T4 is cell studies: how we grade evidence. The 2025 and 2026 animal studies are not cited in FDA’s review.
04Has TB-500 been tested in people?
Not in a published controlled study (PubMed and ClinicalTrials.gov, 21 November 2026). In the published literature we found one uncontrolled report, and the registry holds one trial without results. Reports made to FDA are a separate record; they show no cause and no rate.
- 2003The sequence is tested in mice
FDA staff write that TB-500 appears to have first been made from thymosin β4 in 2003, for a mouse study; that study used the sequence without the acetyl group.
- 2011A veterinary preparation
FDA staff write that a veterinary preparation of TB-500 appeared in 2011 and was marketed in horse and greyhound sports.
- Feb 2026A registered trial starts
NCT07487363, a randomised, placebo-controlled phase 1/2 study planned for 80 patients aged 40 to 75 (no healthy volunteers), began on 5 February 2026. Its primary measures are adverse events.
- Jul 2026FDA’s review
Briefing its compounding advisory committee, FDA staff wrote that “no articles were found in which TB-500 was administered to humans”.
- Sep 2026A three-patient report
A case report described three patients who received TB-500 together with BPC-157, ARA-290, dexamethasone and a local anaesthetic, with no control group.
- Nov 2026No results yet
The trial record, last updated 12 November 2026, shows the trial recruiting, with no results posted and primary completion estimated for February 2027.
The report’s authors write that “causality cannot be established”, and that it is “impossible to determine” whether each course came from one agent, a combination of agents, or the expected natural history. With several agents and no control group, it cannot show anything about TB-500 itself.
The full protein is a separate record. None of the registered trials of the full 43-amino-acid protein, thymosin β4, that we found gave TB-500 (ClinicalTrials.gov, 21 November 2026). A 2026 review in the Journal of the American Academy of Orthopaedic Surgeons calls TB-500 “a distinct seven amino-acid fragment” of thymosin β4 that is “frequently conflated with full-length TB-4 despite the absence of validated biologic or clinical equivalence”. Those trials, side by side with TB-500: TB-500 vs thymosin beta-4.
05What did FDA staff and reviewers conclude?
FDA, on effectiveness. Reviewing TB-500 for the list of substances pharmacies may compound with, FDA staff found “a lack of evidence to evaluate the effectiveness” of TB-500 and its acetate salt for the use nominated to them, on wounds. At the time of their review, they found no report in the medical literature of TB-500 given to patients for any disease or condition.
FDA, on animal and cell work. At the time of their review, FDA staff identified no animal study testing TB-500 itself on wounds, only the 2024 cell study, and concluded that “nonclinical pharmacological evidence is currently lacking”. They found no human study of how the body absorbs and clears TB-500, and no toxicity studies in animals or the laboratory.
An independent review, 2026. The orthopaedic review above, which searched the literature to June 2026, found that none of BPC-157, thymosin β4 and TB-500 has “controlled human orthopaedic efficacy evidence”.
Is TB-500 an approved medicine, where is it restricted, and what have regulators said about its safety? Status by country and the safety statements: the TB-500 guide.
06What we don’t know about TB-500
Whether any effect shows up in people
We found no published controlled study of TB-500 in people, and one registered trial, which measures adverse events and has no results (PubMed and ClinicalTrials.gov, 21 Nov 2026).
Whether older results apply to TB-500
The 2003 mouse study used the sequence without the acetyl group, and another used a modified molecule. FDA staff say such results cannot be directly extrapolated.
How the body handles it
FDA staff found no human study of how TB-500 is absorbed and cleared, and no toxicity studies in animals or the laboratory.
Which molecule a vial holds
As FDA describes it, TB-500 weighs 889.01 g/mol; PubChem lists the full protein at about 4,963 g/mol. The mass result on a lot’s report is the line that shows which one a sample matches.
How to find that line on a lab report: how to read a COA. How a mass result tells the two apart: mass spectrometry explained.
This is a plain-English summary of public documents and studies, checked on 21 Nov 2026. It is not legal or medical advice.